BCR and chronic myelogenous leukemia, BCR-ABL1 positive: It seems evident that the unraveling of the inmost features of the TKI-insensitive stem/progenitor cell population, as well as its interactions with the immune system, may introduce an alternative way to monitor the BCR::ABL1-based molecular response to identify CML patients who achieved a cure/immune control of the disease and may, therefore, safely stop TKI.